The American biotechnology company Novavax and the Serum Institute of India received emergency use authorization for their Covid vaccine in Indonesia. The company also announced that it has filed for approval to Health Canada. The company announced that the submission for the EMA has been completed as well. A new Covid vaccine may soon be available.
Novavax develops next-generation vaccines
The company has been developing next-generation vaccines for several infectious diseases such as Ebola, influenza, and the syncytial virus. Indonesia might receive up to 20 million doses of the Noxaxav vaccine this year. The company applies for emergency authorization in the U.K., Australia, India, and the Philippines as well.
The trials concluded that the protein-based vaccine is 90% or more effective against the new coronavirus and its variants. Novavax sent data, including the results of the Phase III trial with over 30,000 participants from Mexico and the U.S. Another clinical trial from the U.K. with 15.000 participants demonstrated that the NVX-CoV2373 vaccine is 96.4 % effective against the original virus, and it has an overall efficiency of 89.7%. The World Health Organization will review the regulatory filing to decide if the vaccine will be included in the Emergency Use Listing.
What do we know about the Novavax Covid Vaccine?
The NVX-CoV2372 protein vaccine has been developed by sequencing the original SARS-CoV-2 strain. The company further explains the creation process:
NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Each package contains ten doses, and it can be stored at 2-8 degrees Celsius. For a person to be fully vaccinated with the Novavax Covid vaccine, two doses 21 days apart are necessary via intramuscular injection.